(PharmaNewsWire.Com, January 21, 2017 ) The Report, "Small interfering RNA (siRNA) Therapeutics-Competitive Landscape, Technology and Pipeline Insights, 2016" depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.
This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.
There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology.
-Coverage of global siRNA therapies under development across the globe -Competitive landscape of investigational products for key players and key therapy areas -The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies. -Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information. -Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline. -Report analyzes the different emerging delivery technologies by companies and products under development.
-The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA. -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage -Identify and understand important and diverse types of therapeutics under development for siRNA -The siRNA report helps to develop a better understanding of the emerging technologies by the recent acquisitions which are driving the siRNA market -Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline -Devise corrective measures for pipeline projects by understanding siRNA pipeline in-depth -Identifying the upcoming leaders in the siRNA market in the coming year
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
